Bitcoin fell below Strategy Inc’s average purchase price of $76,037, triggering fresh pressure.Bitcoin fell below Strategy Inc’s average purchase price of $76,037, triggering fresh pressure.

Strategy faces mounting challenges under Michael Saylor

2026/02/02 16:15
3 min read

Michael Saylor’s Strategy is starting to fall apart, and there’s no more pretending otherwise. Over the weekend, Cryptopolitan reported that Bitcoin had dropped under $76,000, breaking the line that had been holding up Saylor’s plan for years, which is exactly $76,037, the average level where Strategy Inc. bought its Bitcoin.

And now, Saylor is officially underwater.

The MSTR stock is down nearly 70% from the top. The company isn’t getting a premium on its shares anymore. And it’s getting harder to raise money. The model doesn’t work the way it used to.

Bitcoin’s current crash takes out the last support level

Right now, Strategy owns more than 712,000 BTC. But the value of that stash is shrinking fast. Bitcoin fell to $74,541 on Monday, nearly matching the low of $74,425 from last April, right after Donald Trump won the 2024 election. It’s now the lowest level since then.

The drop finished off a brutal January. Bitcoin lost almost 11% last month, its fourth red month in a row. That hasn’t happened since the crash after the 2017 bull run.

There’s no immediate emergency. There’s no margin call. They don’t have to sell any Bitcoin. And Strategy still has $2.25 billion in cash from past stock deals.

But the bigger issue is, what now? No one’s buying their stock like they used to. Without new buyers, they can’t keep running the same playbook.

Saylor’s whole idea was to sell shares when the price was high, then use that cash to buy more Bitcoin. It was a smart way to build the treasury without borrowing more. That worked when investors were excited. Now that excitement is gone. The Strategy keyword is no longer enough to convince traders. Everyone’s watching other things; AI stocks, gold, silver, whatever’s moving.

Bitcoin also doesn’t act the way it used to. Inflation? Didn’t help. Dollar dropping? Didn’t help. Even when regulators sounded positive, the coin just sat there. People are tired. The narrative’s broken.

Strategy’s stock now trades like a tracker, not a bet

With the stock no longer trading above its Bitcoin value, Strategy can’t pull the same trick again. Selling new shares now would dilute what’s already left, and there’s no upside.

The market cap and the value of the Bitcoin they own are almost the same. So when Bitcoin falls 1 or 2%, it drags the stock down with it. It’s that tight.

Traders expect more losses when U.S. markets open. Gold is down too, after the biggest one-day drop in ten years. Everything’s shaky. And Strategy’s setup depends on confidence. Without that, it’s just a company holding coins.

Want your project in front of crypto’s top minds? Feature it in our next industry report, where data meets impact.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26